Physician profile
Nicole Boyd
NPI 1710439112
$4,229.19
in general payments reported to CMS, 2019-2025
14 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $482 · 2023: $1,007 · 2024: $1,274 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,372 · Education: $15.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,371.56 |
| Education | $15.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,706.02 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $896.37 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $409.78 | 2021-2025 | Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $237.26 | 2024 | Cobenfy |
| Lundbeck LLC | $220.61 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $174.86 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $160.52 | 2023-2025 | Invega Sustenna, Spravato |
| Supernus Pharmaceuticals, INC. | $157.40 | 2023-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $112.07 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $80.42 | 2023-2024 | Trintellix |
| Boston Scientific Corporation | $29.86 | 2025 | Avvigo Guidance System |
| Tris Pharma INC | $15.70 | 2024 | Dyanavel Xr |
| Alkermes, INC. | $15.09 | 2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $13.23 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.